The Lynx Group

Hedgehog Pathway Inhibitor Sonidegib plus Azacitidine in Myeloid Malignancies

Conference Correspondent

A phase 1/1b trial evaluated the safety and effectiveness of the oral smoothened inhibitor sonidegib (LDE225) in combination with azacitidine in 63 patients with myeloid malignancies; the first analysis of the final study results was reported at ASH 2017.

Eligible patients could have untreated and relapsed/refractory (R/R) disease and acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), myelodysplastic syndromes (MDS), MDS/myeloproliferative neoplasms overlap, or myelofibrosis (MF) diagnoses. In the phase 1 (3 + 3) dose-escalation portion of the study, oral sonidegib was started at 400 mg daily continuously (28-day cycle) and azacitidine at 75 mg/m2 for 7 days, with dose adjustment per label. The primary end point of the study was to determine the maximum tolerated dose (MTD) and best overall response of sonidegib plus azacitidine. Dose-limiting toxicity (DLT) in phase 1 was assessed after 42 days at steady-state concentrations of sonidegib.

A total of 62 patients were enrolled (phase 1, 10 patients; phase 1b, 52 patients); of these, 28 (45%) patients were newly diagnosed and 34 (55%) had R/R disease. Among the 62 enrolled patients, 38 (61%) had AML, 18 (29%) had MDS, 4 (6.5%) had CMML, and 2 (3.5%) had MF. Among the 38 AML patients, 15 had untreated AML and 23 had R/R AML; 21 patients had intermediate risk, and 16 patients had unfavorable cytogenetics. The median age of the total study population was 72.5 years (range, 39-86 years) and the majority (66%) were male.

At the sonidegib 400-mg daily dose level (n = 6), 1 DLT of creatine phosphokinase elevation was reported. At a follow-up of 14.5 months, 218 cycles have been administered of the MTD dose of sonidegib 200 mg (n = 56). Dose adjustments were needed in 12.5% of sonidegib-treated patients and in 18% of azacitidine-treated patients; at least once, dose omissions were needed in 71.4% and 18%, respectively.

At the MTD sonidegib dose of 200 mg (n = 56), all patients experienced ≥1 grade 3 adverse events (AEs), which were mostly hematologic in nature and included thrombocytopenia (n = 45), neutropenia (n = 42), anemia (n = 39), and leukopenia (n = 38). The most common nonhematologic grade 1/2 AEs included fatigue (n = 43), constipation (n = 27), nausea (n = 21), cough (n = 18), insomnia (n = 14), diarrhea (n = 16), and abdominal pain (n = 16). Six deaths occurred in the study—4 due to cancer, 2 from cardiac arrest, and 2, sudden death.

At a median follow-up of 14.5 months, the best response (complete response + partial response + morphologic leukemia-free state) was achieved by 2 patients with untreated AML and 2 with R/R AML. Notably, 16 of the 21 (76%) patients with R/R AML had stable disease. Median overall survival was 6.4 months (95% confidence interval [CI], 4.2-10.9) and progression-free survival was 5.3 months (95% CI, 4.0-10.7) in patients with AML.

These results suggest that combination therapy with sonidegib plus azacitidine was associated with a high disease control rate and lack of disease progression, particularly in the R/R AML patient cohort.

Tibes R, et al. 2017 ASH. Abstract 2629.

Related Articles

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: